IL7R and precursor B-cell acute lymphoblastic leukemia: Moreover, B12 or other antibodies such as those described in the accompanying paper by Durum and collaborators, can become valid tools in the clinical arsenal against other cancers, especially B-ALL but also chronic lymphocytic leukemia, other hematological malignancies and even solid tumors with ectopic expression of IL-7R, such as breast and lung cancer, where IL-7 and its receptor have been implicated [56–59].